Timing of Bleeding and Ischemic Events in High-Bleeding Risk Patients Treated With 1-Month DAPT

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Trials

Background:

• Percutaneous coronary intervention (PCI) necessitates antiplatelet therapy.
• Patients at high bleeding risk (HBR) require careful management of dual antiplatelet therapy (DAPT) duration.
• Optimizing treatment strategies requires understanding the balance between bleeding and ischemic risks.

Purpose of the Study:

• To describe the temporal patterns of bleeding and ischemic events after PCI.
• To analyze event timing in HBR patients treated with a 1-month DAPT regimen.

Main Methods:

• Analysis of patient-level data from 7 prospective studies.
• Inclusion of HBR patients treated with PCI and 1-month DAPT.
• Evaluation of the timing of major bleeding (BARC types 3-5) and major adverse cardiovascular events (MACE).

Main Results:

• Among 7,266 HBR patients, 4.0% experienced major bleeding and 6.0% had MACE within one year.
• Both bleeding and MACE rates were highest within the first 30 days post-PCI.
• After 30 days, MACE rates remained significantly higher than bleeding rates.

Conclusions:

• In HBR patients on 1-month DAPT post-PCI, the initial 30 days carry the highest risk for both bleeding and MACE.
• Major adverse cardiovascular events are more frequent than bleeding events beyond the first month.
• Event rates stabilize after the initial period, particularly with transition to single antiplatelet therapy.